Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.60 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.59 |
| ▸ | NPY2R | P49146 | 7/20 | 0.59 |
| ▸ | NPY4R | P50391 | 7/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.59 |
| ▸ | NPY1R | P25929 | 5/20 | 0.59 |
| ▸ | TFPI | P10646 | 1/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.57 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.56 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23895426 | 1.00 | OPRD1 (0.60) | OPRD1NTSR1NPY2RNPY4RNPY5R | |
| SCHEMBL23895420 | 0.95 | OPRD1 (0.62) | OPRD1NTSR1NPY2RNPY4RNPY5R | |
| SCHEMBL30712913 | 0.89 | NPY2R (0.64) | OPRD1NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31182450 | 0.88 | NPY2R (0.66) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30906464 | 0.87 | NPY2R (0.70) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL30607473 | 0.87 | NPY2R (0.63) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29679794 | 0.86 | CXCR4 (0.61) | OPRD1NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29711789 | 0.86 | NPY2R (0.65) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL31182841 | 0.86 | TFPI (0.66) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| SCHEMBL29521469 | 0.86 | NPY2R (0.61) | OPRD1NTSR1NPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308211-A1 | METHOD OF TREATING VIRAL INFECTIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308211-A1 | METHOD OF TREATING VIRAL INFECTIONS | IRF3, IRF2BP2, STAT4 | OPRD1 3957/4885NTSR1 2984/4885NPY2R 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.